The Fisher Wallace Stimulator® is cleared by the FDA to treat depression, anxiety and insomnia and has been proven to be safe and effective in multiple published studies, including a published study of bipolar depression treatment conducted at Mount Sinai Hospital. The following chart from the Mount Sinai study shows a lowering of depression symptoms from active treatment (blue line) versus a return to baseline in the placebo group (red line).
The Fisher Wallace Stimulator® treats depression and anxiety by stimulating the brain to produce serotonin and melatonin while reducing cortisol (the stress hormone) and calming the brain's Default Mode Network. The device is effective in treating the following symptoms of depression and anxiety:
- Decreased energy and fatigue
- Oversleeping or insomnia
- Persistent sadness
- Feelings of hopelessness
- Feelings of worthlessness and/or helplessness
- Loss of interest in activities and hobbies, including sex
- Restlessness and irritability
- Chronic and unsubstantiated worry
- Repeated, random panic attacks
These symptoms are commonly associated with Major Depressive Disorder, Bipolar Disorder, Persistent Depressive Disorder, and Generalized Anxiety Disorder.
Easy to Use
The device is extremely easy to use and the stimulation feels pleasant during the 20-minute treatment session, often causing the patient to feel immediately relaxed. Patients may read a book, watch TV, use the computer or engage in other quiet activities during the treatment session.
Similar to how pharmaceutical drugs must be FDA-Approved to enter the market, medical devices must be FDA-Cleared. The Fisher Wallace Stimulator® is FDA-Cleared for the treatment of depression, anxiety and insomnia. It also has a separate FDA clearance to treat pain on the body. The only patients who are not qualified to use the device are those with implanted medical devices, such as a pacemaker or vagus nerve stimulator. Watch the video in the How It Works section (below) to see how easy it is to use.
The Fisher Wallace Stimulator® treats insomnia by stimulating the brain to produce serotonin and melatonin while reducing cortisol (the stress hormone) and calming the brain's Default Mode Network. The device is effective in treating the following types of insomnia:
- Chronic Insomnia: Difficulty falling asleep or staying asleep three or more nights per week.
- Onset Insomnia: Difficulty falling asleep at the beginning of the night.
- Comorbid Insomnia: Insomnia that occurs in conjunction with depression or anxiety.
- Maintenance Insomnia: Difficulty staying asleep through the night (waking up often or waking up too early).
- Acute Insomnia: Temporary difficulty falling asleep or staying asleep as the result of traveling or a life event.
Easy to Use
The device is extremely easy to use and the stimulation feels pleasant during the 20-minute treatment session, often causing the patient to feel immediately relaxed. To treat insomnia, patients use the device for 20 minutes before bedtime. If you do not suffer from insomnia and only use the device to treat depression or anxiety, the device will not make you drowsy.
Similar to how pharmaceutical drugs must be FDA-Approved to enter the market, medical devices must be FDA-Cleared. The Fisher Wallace Stimulator® is FDA-Cleared for the treatment of insomnia, anxiety and depression. It also has separate FDA clearance to treat pain on the body. The only patients who are not qualified to use the device are those with implanted medical devices, such as a pacemaker or vagus nerve stimulator. Watch the video in the How It Works section (below) to see how easy it is to use.
A retrospective chart review of cranial electrotherapy stimulation for clients newly admitted to residential drug treatment
David A. Deitch, Ph.D., Jennifer Butler, B.S., Charles A. Fisher, Sidney Hargrave, M.A., Norman John 2009
This pilot program was designed to determine if using CES affected retention rates among new drug rehab patients arriving at Phoenix House, the nations largest non-profit drug rehab center. The study included 392 subjects consisting of heroin and cocaine addicts; 293 patients did not receive CES (control) and 99 patients received an average of 5 CES treatments total per patient. A 50% increase in retention after 90 days was seen among patients who received CES versus patients who did not receive CES. Patients who received CES also reported significant decreases in anxiety and insomnia. Phoenix House pilot program poster (link to poster, previous file in dropbox.)
Opiate abstinent syndrome is rapidly blocked by electrostimulation.
Kharchenko EP, Shesternin SL, Klimenko MN.
Dokl Biol Sci. 2001 Nov-Dec;381:516-8. (PubMed link)
Electrostimulation: addiction treatment for the coming millennium.
Patterson MA, Patterson L, Patterson SI.
J Altern Complement Med. 1996 Winter;2(4):485-91.
At a period of fundamental review of the health care system, it is timely to re-assess one of medicine's most intractable problems--the treatment of addictions. The apparently insoluble dilemmas posed by the acute and chronic withdrawal syndromes underlie universally high drop-out and relapse rates. In a decade of HIV and AIDS infection, poly-substance addiction, potent street drugs, and ossified treatment strategies, it is urgent that policy formulators investigate seriously a flexible system of non-pharmacological transcranial electrostimulation treatment, based on its record of rapid, safe, and cost-effective detoxification in several countries, as one innovative contribution to the challenges presented by addiction in the 1990s. This is a brief report of the introduction of NeuroElectric Therapy (NET) into Germany, describing the responses of the first 22 cases. The daily progress of a heroin addict and a methadone addict are detailed: both were treated as outpatients for 8 hours daily, for 7 and 10 days respectively.Open PDF
Effects of cerebral electrical stimulation on alcoholism: a pilot study.
Padjen AL, Dongier M, Malec T.
Alcohol Clin Exp Res. 1995 Aug;19(4):1004-10. (PubMed link)
Cerebral electrical stimulation (CES), born from research on electroanesthesia in the seventies, consists of the application of a pulsating current of small intensity (usually less than 1 mA, and below the threshold of perception) through the skull, e.g., in daily 30-min sessions. Claims of biological effectiveness (neurochemical, hormonal and EEG changes, naloxone-reversible analgesia in rats, etc.) and of clinical effectiveness (anxiety, depression, cognitive functions in alcoholics) have often relied on poorly controlled data. A recent controlled study in the treatment of opiate withdrawal has been positive. The present double-blind controlled study compares active CES with sham stimulation in 64 alcohol-dependent males. Over 4 weeks, both treatment groups improved significantly in most aspects. In the active treatment group additional significant improvement was observed in week-end alcohol consumption, and in two psychological measures: depression and stress symptoms index, but not in general drinking behavior.Open PDF
The administration of transcranial electric treatment for affective disturbances therapy in alcoholic patients.
Krupitsky EM, Burakov AM, Karandashova GF, Katsnelson JaS, Lebedev VP, Grinenko AJa, Borodkin JuS.
Drug Alcohol Depend. 1991 Jan;27(1):1-6. (PubMed link)
In a double blind placebo-controlled investigation it was shown that transcranial electric treatment (TET), comprising the combination of a constant current with a pulse current of square impulses of 70-80 Hz is an effective method to correct affective disturbances (anxiety, depression) in alcoholic patients. The medical effects of TET are accompanied by changes in the metabolism of GABA and monoamines, but not of beta-endorphin, and also by a decrease in the latency of alpha-rhythm appearance after closing of the eyes.Open PDF
Transcutaneous electrical stimulation with Limoge current potentiates morphine analgesia and attenuates opiate abstinence syndrome.
Auriacombe M, Tignol J, Le Moal M, Stinus L.
Biol Psychiatry. 1990 Oct 15;28(8):650-6. (PubMed link)
Transcutaneous electrostimulation is a somewhat controversial technique used in the management of the opiate withdrawal syndrome. We report an animal study of a particular transcutaneous electrostimulation called transcutaneous cranial electrostimulation, based on a technique used for many years on heroin addicts for the rapid severance of their addiction, which has been validated in a clinical setting by a double-blind trial. This technique involves the application of an intermittent high-frequency current (Limoge's current). Our experimental data show that this transcutaneous cranial electrostimulation increases morphine analgesia by threefold on the tail flick latency measure and produces a 48% attenuation of the abstinence syndrome observed after abrupt cessation of morphine administration. These results were obtained using a double-blind paradigm.Open PDF
Treatment of drug, alcohol and nicotine addiction by neuroelectric therapy: analysis of results over 7 years
Patterson MA, Firth J, Gardiner R.
J Bioelectricity 1984; 3:193-221
NeuroElectric Therapy (NET) is a 10-day treatment with a transistorized stimulator, which rapidly reduces both acute and chronic withdrawal symptomatology of all chemical substances, without drugs and with no negative side-effects. It is hypothesized that NET acts by specific electrical frequency stimulation of endorphin production that has been decreased due to chronic substance abuse. This has been demonstrated using NET in rat models; corticosterone levels and hepatic enzyme activity were also significantly altered. Of 186 patients, 98.4% were successfully detoxified, with marked feeling of well-being and no craving (in 95%) or anxiety (in 75%). Detailed assessments of abstinence syndrome in NET are given. Of a 50% response to follow-up, 78.5% were addiction-free (80.3% of drug addicts) 1 to 8 years after NET, although average time in rehabilitation was only 16 days. Alcohol, marijuana and cigarette use were decreased in 64%. Diminished substance use was reported in 76% of recidivists.Open PDF
Cranial electrotherapy stimulation treatment of cognitive brain dysfunction in chemical dependence.
Schmitt R, Capo T, Frazier H, Boren D.
J Clin Psychiatry. 1984 Feb;45(2):60-1, 62-3. (PubMed link)
Several studies have shown that cranial electrotherapy stimulation (CES) is useful in treating brain dysfunction associated with alcoholism. A double-blind study replicated the latest of these findings in 60 inpatients and extended them by treating individuals with alcoholism and other chemical dependencies. Treatment effects were assessed on three subscales of the WAIS that are clinical indicators of organic brain syndrome. No placebo effect was found. CES appears to be a valuable adjunct to rehabilitation programs for addicted persons and can effect changes in areas not addressed by other treatment modalities.Open PDF
Electrosleep (electrical transcranial stimulation) in the treatment of anxiety, depression and sleep disturbance in chronic alcoholics.
McKenzie, Richard E.; Costello, Raymond M.; Buck, Don C.
Journal of Altered States of Consciousness, Vol 2(2), 1975-1976, 185-196.
Employed a double-blind design with treatment variables of current and suggestion, and outcome criteria of anxiety, depression, and sleep disturbance to test for effects of electrosleep (electrical transcranial stimulation) in 20 male hospitalized alcoholics (mean age, 51 yrs). Ss were randomly assigned to 1 of 4 groups; 2 groups received current and 2 did not; 1 current and 1 noncurrent group received sensation, the other 2 did not. Current was standardized at 1 mA; peak-to-peak amplitude was manipulated to control for physical sensation. Five outcome criteria were employed: 3 depression indices, 1 index of anxiety, and 1 index of quality of sleep. Results suggest that electrosleep could have both a direct effect attributable to intracranial current flow and an indirect effect attributable to the psychological influence of suggestion.Open PDF
The effects of cerebral electrotherapy on short-term memory impairment in alcoholic patients.
Smith, Ray B.; Day, Eleanor
International Journal of the Addictions, Vol 12(4), Jun 1977, 575-582.
Two hundred twenty-seven male alcoholism patients were placed into four therapy and onc control groups. The therapy groups received cerebral electrotherapy (CET) for 40 minutes a day, Monday through Friday for 3 weeks. Groups I and II assisted the therapist in setting the current to just below sensation threshold. Group I via headbands (X = 0.40 mA) and Group II via ear stethoscopes (X = 0.21 mA). Two other groups received 0.10 and 0.20 mA respectively via ear stethoscope electrodes. It was found that CET significantly reduced brain dysfunction in all treatment groups when compared with controls as measured by the Benton Visual Retention Test.Open PDF
Treatment of methadone withdrawal with cerebral electrotherapy (electrosleep).
Gomez E, Mikhail AR.
Br J Psychiatry. 1979 Jan;134:111-3. (PubMed link)
The use of cerebral electrotherapy (CET) in methadone detoxification was studied in 28 patients. Fourteen patients received active CET; the other 14 acted as controls and received either stimulated CET or only methadone detoxification therapy. One patient dropped out of the study. The Taylor Manifest Anxiety Scale and the Hamilton Anxiety Scale were administered before and after the study period. Nine of the patients receiving active CET were drug-free by the end of 8 to 10 days, and all experienced a marked reduction of their symptoms; the control group did not show significant changes. CET was clearly beneficial in the treatment of patients undergoing methadone withdrawal.Open PDF
Doctor & Patient Testimonials
A Real Patient and Doctor Discuss the Fisher Wallace Stimulator®
Does it work? Columbia University psychiatrist Richard P. Brown says he has used the device with 400 severely depressed patients and that more than 70% find relief -- about twice the rate of anti-depressants.
– The Wall Street Journal
Treat Symptoms with Medical-Grade Technology
Designed collaboratively by world-class engineers and doctors, the Fisher Wallace Stimulator® uses proprietary waveforms to gently stimulate the brain to produce serotonin and other neurochemicals responsible for healthy mood and sleep. Proven safe and effective in multiple published studies, the device is cleared by the FDA to treat depression, anxiety and insomnia.
Watch the video to learn how easy it is to use.
Start Your 30-Day Trial
to Use the Device
Answer a few simple questions on purchase-authorization.com.
This process takes less than 60 seconds.
Go to purchase-authorization.com to obtain same-day authorization, or have your provider fax or email a prescription or completed authorization form to Fisher Wallace. The FDA requires authorization for US patients.
Try It for 30 Days
Finance Your Purchase with or .
If you prefer PayPal, checkout with PayPal and choose PayPal Credit for no payments due for six months. Or checkout with Bread to finance your purchase for up to 24 months. Applying for Bread will not affect your credit score.
Compare the Fisher Wallace Stimulator® to Drug Therapy, TMS, ECT and tDCS for the treatment of depression, anxiety, insomnia and chronic pain.
|TMS||Drug Therapy||ECT||tDCS||Fisher Wallace Stimulator®|
|FDA-Cleared for Depression||No|
|FDA-Cleared for Insomnia||No||No||No|
|FDA-Cleared for Anxiety||No||No||No|
|FDA-Cleared for Pain||No||No||No|
|Free of Serious Side Effects||No||No|
|Use at Home||No||No||No|
|30-Day Return / Refund Policy||No||No||No||No|
Return Policy & Insurance Reimbursement
Customers may return the Fisher Wallace Stimulator® within 30 days of receipt. The Fisher Wallace Stimulator is effective for the majority of patients within the first two weeks of daily use, but some customers may require three to four weeks to experience positive results. If you need a few extra days, or even a couple of extra weeks, we would be delighted to extend the refund period beyond 30 days. We would prefer that you have ample time to judge the effectiveness of our technology rather than returning it prematurely.
To request more time, simply call 800 692 4380 or email us at email@example.com.
If you ultimately decide to return the device for a refund, please see our refund policy.
Insurance Reimbursement Process
Many but not all private insurance companies, such as Aetna, United Healthcare and Blue Cross have reimbursed patients for the purchase of the Fisher Wallace Stimulator®, especially when it is used for the treatment of pain. Fisher Wallace does not process reimbursement claims on behalf of patients, so we recommend that you contact your insurance provider to confirm coverage and the details of their reimbursement process. A letter of medical necessity may be required to obtain coverage. You may download a template of this letter. For more information on the reimbursement process, please click here.